Irish drug maker Elan said it would return $1 billion to shareholders, refinance debt and make acquisitions after the $3.25 billion sale of its stake in a multiple sclerosis drug to Biogen Idec.
WSJ.com: What's News US, Wall Street Journal
Fri, 02/22/2013 - 8:28am
Irish drug maker Elan said it would return $1 billion to shareholders, refinance debt and make acquisitions after the $3.25 billion sale of its stake in a multiple sclerosis drug to Biogen Idec.